MEDLATEC PinkCare – Women's Hereditary Cancer Risk Test

PinkCare is a hereditary cancer genetic risk assessment offered by MEDLATEC, designed to identify inherited genetic variants associated with susceptibility to certain cancers.

The test analyses a panel of 10 genes associated with hereditary cancer risk, focusing on breast, ovarian and colorectal cancers.

Unlike tests that screen for cancer-associated signals in the blood, PinkCare evaluates inherited genetic susceptibility. It does not determine whether cancer is currently present.

Cancer Risks Assessed

• Breast Cancer

Assessment of inherited genetic variants associated with an increased susceptibility to breast cancer.

• Ovarian Cancer

Analysis of genetic variants that may be associated with hereditary ovarian cancer risk.

• Colorectal Cancer

Evaluation of inherited genetic factors associated with susceptibility to certain forms of colorectal cancer.

Key Benefits of PinkCare

• Personalised Hereditary Cancer Risk Assessment

PinkCare provides information about inherited genetic factors that may influence an individual's susceptibility to selected cancers.

• Focused 10-Gene Panel

The test analyses 10 genes associated with hereditary cancer risk, focusing on breast, ovarian and colorectal cancers.

• Supports Preventive Healthcare Planning

Results may help patients and healthcare professionals discuss appropriate screening strategies, further genetic assessment and personalised healthcare planning.

• Provides Information Relevant to Family Health

Some inherited genetic findings may have implications for biological relatives. Genetic counselling can help patients understand whether additional family risk assessment is appropriate.

• Generally a One-Time Genetic Assessment

Inherited genetic variants are generally stable throughout life. Routine annual repetition of the same germline genetic test is therefore usually unnecessary, although additional testing may be appropriate as medical knowledge or individual circumstances change.

Who May Consider PinkCare?

PinkCare may be considered by individuals who:

• Have a family history of breast, ovarian or colorectal cancer.

• Have relatives diagnosed with cancer at a relatively young age.

• Have multiple biological relatives affected by related cancers.

• Have a personal history that raises concern about hereditary cancer susceptibility.

• Have been advised by a healthcare professional to consider genetic testing.

• Want to understand inherited cancer risk as part of a preventive healthcare plan.

The suitability of genetic testing should be assessed based on individual medical history, family history and professional guidance.

Testing Process

1. Pre-Test Consultation: Review medical history, family cancer history and genetic testing suitability.

2. Sample Collection: A biological sample is collected according to MEDLATEC's laboratory requirements.

3. Genetic Analysis: The laboratory examines the selected 10-gene panel for relevant genetic variants.

4. Results: Results are generally expected in approximately 15 working days, subject to laboratory confirmation.

5. Genetic Counselling and Follow-Up: A qualified healthcare professional may explain the findings and recommend appropriate next steps.

Understanding Your Results

• Pathogenic or Likely Pathogenic Variant

A clinically significant inherited genetic variant may indicate increased susceptibility to certain cancers. It does not mean that cancer is currently present or will definitely develop.

• No Reportable Pathogenic Variant Identified

A negative result does not eliminate hereditary or non-hereditary cancer risk. Other genetic factors, family history and environmental influences may still contribute to an individual's overall risk.

• Variant of Uncertain Significance (VUS)

Some genetic changes cannot currently be classified as harmful or harmless. These findings generally should not independently determine clinical management.

Key Data

• Test Name: PinkCare

• Test Category: Hereditary Cancer Genetic Risk Assessment

• Genetic Panel: 10 Genes

• Cancer Risks Assessed: Breast, Ovarian and Colorectal Cancers

• Purpose: Assessment of Inherited Cancer Susceptibility

• Expected Result Time: Approximately 15 Working Days

Your Healthcare Journey in Vietnam with MediHub

MediHub supports international patients travelling to Vietnam for healthcare services, including genetic testing and preventive healthcare planning.

Our support services may include:

• Healthcare service and genetic testing consultation

• Appointment scheduling with MEDLATEC

• Pre-arrival guidance and preparation

• Visa and travel assistance where required

• Airport transfers and local transportation

• Accommodation arrangements

• Medical interpreter coordination

• Assistance during medical appointments

• Medical results and follow-up coordination

• Travel and tourism arrangements during your stay

Plan Your Genetic Testing Journey in Vietnam

Interested in understanding your hereditary cancer risk?

Contact MediHub for personalised assistance in planning your genetic testing journey in Vietnam. Our team can help coordinate your PinkCare appointment with MEDLATEC, provide pre-arrival guidance and assist with travel and follow-up arrangements.

Important Medical Information

PinkCare is a hereditary genetic risk assessment, not a test for diagnosing cancer or detecting an existing tumour.

An increased genetic risk does not mean cancer will necessarily develop, and a negative result does not eliminate cancer risk.

Genetic testing results should be interpreted by qualified healthcare professionals, ideally with access to genetic counselling. Recommended cancer screening and clinical assessment may still be necessary regardless of the genetic test result.